
REPL
Replimune Group Inc
Biotechnology
Replimune Group Inc (REPL) Stock News
The latest REPL headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Replimune Group, Inc. for potential securities law violations related to allegedly false or misleading statements. The company received a complete response letter from the FDA regarding its BLA for RP1 in combination with nivolumab for advanced melanoma treatment, citing disagreement over data suitability. Following this announcement on April 10, 2026, Replimune's stock price fell approximately 64.3% on April 13, 2026.